Celcuity (NASDAQ:CELC) Posts Earnings Results, Misses Estimates By $0.28 EPS

Celcuity (NASDAQ:CELC) released its quarterly earnings data on Thursday. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28), Zacks reports. The firm had revenue of $0.09 million during the quarter, compared to analyst estimates of $4.42 million.

Here are the key takeaways from Celcuity’s conference call:

• REVTORPYK was FDA-approved for HR-positive, HER2-negative advanced breast cancer without detected PIK3CA mutations, and both its doublet and triplet regimens received preferred Category 1 recommendations in the NCCN guidelines.
• In the PIK3CA-mutant VIKTORIA-1 cohort, gedatolisib-based regimens significantly improved median progression-free survival to approximately 11 months versus 5.6 months for alpelisib plus fulvestrant, while treatment discontinuation due to adverse events was lower for gedatolisib. Celcuity plans to submit an sNDA in the third quarter of 2026.
• Celcuity remains confident that commercial shipments will begin in late Q3 2026. The company has completed its commercial infrastructure, deployed 88 oncology sales specialists, begun an expanded-access program, and estimates a U.S. addressable market exceeding $6 billion annually.
• The VIKTORIA-2 first-line breast cancer program has been expanded to include endocrine-sensitive patients, potentially broadening gedatolisib’s use across most newly diagnosed advanced HR-positive, HER2-negative patients. Celcuity also expects to provide additional prostate cancer data in Q4 2026.
• Second-quarter net loss widened to $78.9 million from $45.3 million year over year, while selling, general and administrative expenses rose sharply due to launch preparation. The company ended June with $754 million in cash and investments and expects funding into 2029, helped by a $575 million convertible-note offering.

Celcuity Price Performance

CELC stock traded up $5.40 during midday trading on Friday, hitting $92.00. 1,333,092 shares of the stock were exchanged, compared to its average volume of 1,113,413. The stock’s 50-day moving average price is $93.81 and its 200-day moving average price is $108.56. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. The stock has a market cap of $4.49 billion, a price-to-earnings ratio of -23.59 and a beta of 0.20. Celcuity has a fifty-two week low of $44.42 and a fifty-two week high of $151.02.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Weiss Ratings raised Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. HC Wainwright reaffirmed a “buy” rating and issued a $155.00 target price on shares of Celcuity in a report on Friday. Stifel Nicolaus decreased their price target on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a research note on Friday. Citigroup restated an “outperform” rating on shares of Celcuity in a research note on Wednesday, July 15th. Finally, Guggenheim reiterated a “buy” rating on shares of Celcuity in a research note on Wednesday, June 3rd. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Celcuity presently has an average rating of “Moderate Buy” and an average target price of $153.64.

Key Stories Impacting Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $155 price target, implying substantial upside from recent trading levels. Benzinga analyst rating
• Positive Sentiment: Investor sentiment is being supported by the FDA approval of REVTORPYK and its rapid inclusion in the NCCN Category 1 guidelines. The treatment’s VIKTORIA-1 data showed strong efficacy and tolerability, potentially supporting rapid physician adoption and blockbuster commercial potential. Celcuity reportedly has approximately $754 million in cash, providing funding visibility through 2029 despite elevated launch spending. Celcuity REVTORPYK commercial story
• Neutral Sentiment: Stifel Nicolaus retained its Buy rating but reduced its price target to $150 from $175, while Needham maintained Buy and cut its target to $140 from $157. The reductions suggest analysts remain constructive on Celcuity’s long-term opportunity but are adjusting valuation assumptions after recent results and launch considerations. Stifel analyst rating Needham analyst rating
• Negative Sentiment: Second-quarter results showed a $1.44-per-share loss versus the $1.16 consensus estimate, while revenue of approximately $0.09 million was well below the $4.42 million expectation. Analysts subsequently reduced forecasts, highlighting near-term execution risk and the financial impact of commercial launch investments. Celcuity second-quarter 2026 results

Institutional Trading of Celcuity

Large investors have recently modified their holdings of the business. CIBC Private Wealth Group LLC acquired a new position in Celcuity in the fourth quarter valued at $202,000. Xponance LLC acquired a new stake in Celcuity in the 4th quarter worth about $251,000. NorthRock Partners LLC acquired a new stake in Celcuity in the 3rd quarter worth about $294,000. Perbak Capital Partners LLP purchased a new stake in Celcuity in the 3rd quarter valued at about $200,000. Finally, FORA Capital LLC purchased a new stake in Celcuity in the 3rd quarter valued at about $248,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.